NCT01362608 - Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective | Biotech Hunter

Enrollment

136

Participants

Timeline

Start Date

June 20, 2011

Primary Completion Date

May 19, 2015

Study Completion Date

May 19, 2015

Conditions

Gouty Arthritis

Interventions

DRUG

Canakinumab, ACZ885

Canakinumab and placebo matching to triamcinolone acetonide

DRUG

Triamcinolone acetonide

Triamcinolone acetonide 40 mg and placebo matching to canakinumab

Trial Locations (20)

100029

Novartis Investigative Site, Beijing

100044

Novartis Investigative Site, Beijing

100730

Novartis Investigative Site, Beijing

119074

Novartis Investigative Site, Singapore

200127

Novartis Investigative Site, Shanghai

200433

Novartis Investigative Site, Shanghai

210029

Novartis Investigative Site, Nanjing

230001

Novartis Investigative Site, Hefei

230022

Novartis Investigative Site, Hefei

310009

Novartis Investigative Site, Hangzhou

430022

Novartis Investigative Site, Wuhan

510080

Novartis Investigative Site, Guangzhou

529889

Novartis Investigative Site, Singapore

610041

Novartis Investigative Site, Chengdu

610072

Novartis Investigative Site, Chengdu

710032

Novartis Investigative Site, Xi’an

C1015ABO

Novartis Investigative Site, Ciudad Autonoma de Bs As

40-084

Novartis Investigative Site, Katowice

60-773

Novartis Investigative Site, Poznan

50-349

Novartis Investigative Site, Wroclaw